Suppression of breast cancer growth and angiogenesis by an antisense oligodeoxynucleotide to p21Waf1/Cip1

Cancer Letters

Volumn 189, Issue 1, 2003, Pages 39-48

  Weiss, Robert H ^a,b,c   Marshall, Debbie ^b   Howard, Laura ^a   Corbacho, Ana M ^a   Cheung, Anthony T ^b   Sawai, Earl T ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Antisense; Breast cancer; Oligodeoxynucleotide; P21Waf1 Cip1

Indexed keywords

COMPLEMENTARY DNA; OLIGODEOXYNUCLEOTIDE; PHOSPHOROTHIOIC ACID; PROTEIN P21;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER GROWTH; CANCER THERAPY; CAPILLARY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENETIC TRANSFECTION; GROWTH INHIBITION; IMPLANT; IN VITRO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR REGRESSION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; PILOT PROJECTS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

MUS MUSCULUS;

EID: 0037427570     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00495-0     Document Type: Article

References (39)

1. National Cancer Institute . What You Need to Know About Breast Cancer. 2000;National Cancer Institute, Bethesda, MD.
2. 1-phase progression. Genes Dev. 13:1999;1501-1512.
3. LaBaer J., Garrett M.D., Stevenson L.F., Slingerland J.M., Sandhu C., Chou H.S., Fattaey A., Harlow E. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:1997;847-862.
4. Cheng M., Sexl V., Sherr C.J., Roussel M.F. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc. Natl. Acad. Sci. USA. 95:1998;1091-1096.
5. Zhang H., Hannon G.J., Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 8:1994;1750-1758.
6. Waf1/Cip1 is an assembly factor required for PDGF-induced vascular smooth muscle cell proliferation. J. Biol. Chem. 275:2000;10285-10290.
7. Li Y., Dowbenko D., Lasky L.A. AKT/PKB phosphorylation of p21Cip1/WAF1 enhances protein stability of p21Cip1/WAF1 and promotes cell survival. J. Biol. Chem. 276:2001;11352-11361.
8. Asada M., Yamada T., Ichijo H., Delia D., Miyazono K., Fukumuro K., Mizutani S. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 18:1999;1223-1234.
9. Testa J.R., Bellacosa A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. USA. 98:2001;10983-10985.
10. Stein C.A. The experimental use of antisense oligonucleotides: a guide for the perplexed. J. Clin. Invest. 108:2001;641-644.
11. Tian H., Wittmack E.K., Jorgensen T.J. p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res. 60:2000;679-684.
12. Cheung A.T.W., Young L.J.T., Chen P.C.Y., Chao C.Y., Ndoye A., Barry P.A., Muller W.J., Cardiff R.D. Microcirculation and metastasis in a new mouse mammary tumor model system. Int. J. Oncol. 11:1997;69-77.
13. Sawai E.T., Hamza M.S., Ye M., Shaw K.E., Luciw P.A. Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef. J. Virol. 74:2000;2038-2045.
14. Weiss R.H., Maga E.A., Ramirez A. MEK inhibition augments Raf activity, but has variable effects on mitogenesis, in vascular smooth muscle cells. Am. J. Physiol. 274:1998;C1521-C1529.
15. Fan S., Chang J.K., Smith M.L., Duba D., Fornace A.J. Jr., O'Connor P.M. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene. 14:1997;2127-2136.
16. Stewart Z.A., Mays D., Pietenpol J.A. Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Cancer Res. 59:1999;3831-3837.
17. Cheng M., Olivier P., Diehl J.A., Fero M., Roussel M.F., Roberts J.M., Sherr C.J. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18:1999;1571-1583.
18. Yu Q., Geng Y., Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 411:2001;1017-1021.
19. Crooke S.T., Lebleu B., Antisense Research and Applications. 1993;CRC Press, Boca Raton, FL.
20. Guy C.T., Cardiff R.D., Muller W.J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12:1992;954-961.
21. Weiss R.H., Randour C. The permissive effect of p21Waf1/Cip1 on DNA synthesis is dependent on cell type: effect is absent in p53-inactive cells. Cell. Signal. 12:2000;413-418.
22. Folkman J. What is the evidence that tumors are angiogenesis dependent? (editorial). J. Natl. Cancer Inst. 82:1990;4-6.
23. Waldman T., Lengauer C., Kinzler K.W., Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21 (see comments). Nature. 381:1996;713-716.
24. Embury S.H., Mohandas N., Paszty C., Cooper P., Cheung A.T. In vivo blood flow abnormalities in the transgenic knockout sickle cell mouse. J. Clin. Invest. 103:1999;915-920.
25. Montesano R., Orci L., Vassalli P. In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J. Cell Biol. 97:1983;1648-1652.
26. Wouters B.G., Giaccia A.J., Denko N.C., Brown J.M. Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res. 57:1997;4703-4706.
27. Zhou B.P., Liao Y., Xia W., Spohn B., Lee M.H., Hung M.C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 3:2001;245-252.
28. Rossig L., Jadidi A.S., Urbich C., Badorff C., Zeiher A.M., Dimmeler S. Akt-dependent phosphorylation of p21Cip1 regulates PCNA binding and proliferation in endothelial cells. Mol. Cell. Biol. 21:2001;5644-5657.
29. Roman M., Martin-Orozco E., Goodman J.S., Nguyen M.D., Sato Y., Ronaghy A., Kornbluth R.S., Richman D.D., Carson D.A., Raz E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3:1997;849-854.
30. Horner A.A., Raz E. Immunostimulatory sequence oligodeoxynucleotide: a novel mucosal adjuvant. Clin. Immunol. 95:2000;S19-S29.
31. Van Uden J., Raz E. Introduction to immunostimulatory DNA sequences. Springer Semin. Immunopathol. 22:2000;1-9.
32. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6:2000;389-395.
33. Cardiff R.D. Validity of mouse mammary tumour models for human breast cancer: comparative pathology. Microsc. Res. Tech. 52:2001;224-230.
34. Cardiff R.D., Anver M.R., Gusterson B.A., Hennighausen L., Jensen R.A., Merino M.J., Rehm S., Russo J., Tavassoli F.A., Wakefield L.M., Ward J.M., Green J.E. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene. 19:2000;968-988.
35. Deng C., Zhang P., Harper J.W., Elledge S.J., Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 82:1995;675-684.
36. Fantl V., Stamp G., Andrews A., Rosewell I., Dickson C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 9:1995;2364-2372.
37. Sicinski P., Donaher J.L., Parker S.B., Li T., Fazeli A., Gardner H., Haslam S.Z., Bronson R.T., Elledge S.J., Weinberg R.A. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell. 82:1995;621-630.
38. Crooke S.T. Therapeutic Applications of Oligonucleotides. 1995;R.G. Landes, Austin, TX.
39. Monia B.P., Johnston J.F., Geiger T., Muller M., Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 2:1996;668-675.